Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Response Evaluation Criteria in Bone Metastases: Performance and Association of Response Classifications with Survival Outcomes.

Radiology·2026

Same author

Efficacy and Safety of Fibroblast Activation Protein Targeted Radioligand Therapy for Advanced Solid Tumour: A Systematic Review and Meta-Analysis.

Dose-response : a publication of International Hormesis Society·2026

Same author

Global Peatland Carbon Pool Sizes: Current Estimates, Uncertainties, and Future Research Directions.

Global change biology·2026

Same author

FAPI PET/CT shows favorable potential for the evaluation of gallbladder cancer: a prospective study comparing [<sup>68</sup>Ga]Ga-FAPI-04 and [<sup>18</sup>F]FDG.

EJNMMI research·2026

Same author

Recent Advances in Flavonoids and Chronic Disease: Mechanisms, Therapeutic Applications, and Future Directions.

Current medicinal chemistry·2026

Same author

Respiratory syncytial virus (RSV) antibody and small-molecule drugs: current status of clinical translation and challenges.

Frontiers in microbiology·2026

Search research articles

Related Experiment Video

Updated: Oct 25, 2025

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

FAPI PET/CT research progress in digestive system tumours.

Dengsai Peng¹, Jing He², Hanxiang Liu¹

¹Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No 25 TaiPing St, Jiangyang District, Luzhou, Sichuan 646000, PR China; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan 646000, PR China; Academician (Expert) Workstation of Sichuan Province, 646000, PR China.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

|August 8, 2021

Summary

This summary is machine-generated.

New positron emission tomography/computed tomography imaging agents targeting fibroblast activation protein inhibitors show promise for diagnosing and treating digestive system cancers, overcoming limitations of current fluorodeoxyglucose methods.

Keywords:

(68)Ga-FAPI Contrast imaging Digestive system tumour PET/CT

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Experiment Videos

Last Updated: Oct 25, 2025

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Area of Science:

Oncology
Medical Imaging
Radiochemistry

Background:

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is a valuable tool for cancer management but has limitations in diagnosing digestive system tumours.
Fibroblast activation protein (FAP) is highly expressed in gastrointestinal tumours, presenting a potential therapeutic and diagnostic target.

Purpose of the Study:

To review the current research status of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) in various malignant digestive system tumours.
To highlight the advantages of FAPI PET/CT over FDG PET/CT for diagnosing and treating digestive system cancers.

Main Methods:

Review of current literature on FAPI PET/CT in oesophageal cancer, gastric cancer, and liver cancer.
Comparison of FAPI PET/CT imaging characteristics with FDG PET/CT.

Main Results:

FAPI PET/CT demonstrates high tumour uptake and low background uptake in critical organs, offering superior contrast for tumour visualization.
FAPI PET/CT effectively visualizes primary tumours, metastases, and regional lymph nodes in digestive system cancers.
FAPI PET/CT provides a potential new avenue for the treatment of these malignancies.

Conclusions:

FAPI PET/CT imaging represents a significant advancement over FDG PET/CT for the diagnosis and staging of digestive system tumours.
FAPI-targeted therapies offer a promising new approach for managing gastrointestinal cancers.